Market Analysts see Moderna Inc. [MRNA] falling to $101. Time to buy?

Moderna Inc. [NASDAQ: MRNA] stock went on a downward path that fall over -0.85% on Wednesday, amounting to a one-week price increase of more than 9.82%. The company report on November 9, 2022 that Moderna to Present at the Jefferies 2022 London Healthcare Conference.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, Nov. 16th at 8:30 a.m. ET.

A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for at least 30 days following the presentation.

Over the last 12 months, MRNA stock dropped by -31.09%. The one-year Moderna Inc. stock forecast points to a potential upside of 20.52. The average equity rating for MRNA stock is currently 2.50, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $62.08 billion, with 396.00 million shares outstanding and 353.89 million shares in the current float. Compared to the average trading volume of 4.96M shares, MRNA stock reached a trading volume of 3798333 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Moderna Inc. [MRNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $205.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

SVB Leerink have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on October 21, 2022. The new note on the price target was released on September 08, 2022, representing the official price target for Moderna Inc. stock.

The Average True Range (ATR) for Moderna Inc. is set at 8.94, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 2.70. The Price to Book ratio for the last quarter was 3.59, with the Price to Cash per share for the same quarter was set at 20.76. Price to Free Cash Flow for MRNA in the course of the last twelve months was 6.74 with Quick ratio for the last quarter at 1.70.

MRNA Stock Performance Analysis:

Moderna Inc. [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.82. With this latest performance, MRNA shares gained by 35.20% in over the last four-week period, additionally plugging by 32.23% over the last 6 months – not to mention a drop of -31.09% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 67.29, with the RSI for the last a single of trading hit 71.66, and the three-weeks RSI is set at 63.09 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 134.73, while it was recorded at 159.55 for the last single week of trading, and 148.34 for the last 200 days.

Insight into Moderna Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of +71.89 and a Gross Margin at +84.53. Moderna Inc.’s Net Margin is presently recorded at +66.27.

Return on Equity for this stock inclined to 146.08, with Return on Assets sitting at 75.78.

Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.00.

Moderna Inc. [MRNA] Insider Position Details

There are presently around $40,178 million, or 64.20% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,280,023, which is approximately -0.614% of the company’s market cap and around 5.40% of the total institutional ownership; VANGUARD GROUP INC, holding 27,648,457 shares of the stock with an approximate value of $4.51 billion in MRNA stocks shares; and BLACKROCK INC., currently with $4.28 billion in MRNA stock with ownership of nearly -8.561% of the company’s market capitalization.

426 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 17,615,284 shares. Additionally, 466 investors decreased positions by around 19,380,457 shares, while 172 investors held positions by with 209,178,620 shares. The mentioned changes placed institutional holdings at 246,174,361 shares, according to the latest SEC report filing. MRNA stock had 94 new institutional investments in for a total of 4,085,590 shares, while 122 institutional investors sold positions of 483,632 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here